Learning objectives

After attending this webinar, participants will be able to:

• Describe the role of FLT3-ITD and -TKD mutations in AML pathogenesis and distinguish between their molecular and clinical characteristics.
• State the impact of FLT3-ITD vs -TKD mutations on diagnosis, prognosis, and personalized treatment selection for patients with AML.
• Recall key clinical trial data for FLT3 inhibitors in FLT3-ITD- and -TKD-mutated AML and explain their clinical implications.
• Describe considerations for personalizing treatment strategies for patients with FLT3-ITD- and -TKD-mutated AML, including managing relapse and resistance to FLT3 inhibitors.